Apexigen, Inc. (APGN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Carlos, CA, United States. The current CEO is Xiaodong Yang.
APGN has IPO date of 2021-02-22, 11 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $9.57M.
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.
